H
Loading...
Loading...
CDC PLACES (2023, crude) estimates 13% of adults in Bridgeport have diagnosed diabetes — 1.0 points above the U.S. 12% figure. Census population 148,529. Connecticut Medicare wound biologics: National Government Services (NGS) (JK). Hawk Medical is a national HCT/P 361 and wound-care distributor serving licensed Bridgeport clinics — not a walk-in office.
Written for licensed providers. Reviewed by Joe Bradley, Founder & CEO. Content version 2026-09-18. Hawk Medical ships nationwide — this is not a Bridgeport storefront.
361 HCT/P Compliant Tissue Products in Bridgeport, CT for clinics & physicians. Exclusively 361 HCT/P comp… Compliance support & pricing — contact Hawk Medical.
Joe Bradley will tell you the same thing he tells his own staff: epidemiology first, then MAC, then SKU. CDC PLACES (2023, crude) estimates 13% of adults in Bridgeport have diagnosed diabetes — 1.0 points above the U.S. 12% figure. 21.4% of adults 18–64 here currently lack health insurance (CDC PLACES ACCESS2, 2023). Cash-pay PRP and Medicare CTPs cannot share one consent script. Then we pick 361 hctp compliant products against that mix.
National 361 HCT/P Compliant Tissue Products notes (how the product actually works)CDC PLACES (2023, crude) estimates 13% of adults in Bridgeport have diagnosed diabetes — 1.0 points above the U.S. 12% figure. Adult obesity in Bridgeport is 33.5% (CDC PLACES 2023). That shows up in wound offloading and in joint-preservation volume — not as a slogan. Adult arthritis here is 21.1% (CDC PLACES 2023, crude). That is the joint-pain backdrop for PRP and orthobiologics — not a promise that every arthritic knee is a candidate. Payer geography: JK / National Government Services (NGS), sibling states MA, ME, NH, NY, RI, VT. Connecticut Department of Public Health is the public-health home. We will not mash those grains into a fake “demand score.”
If you already buy 361 hctp compliant products elsewhere, use this page as a check: homologous-use language, current National Government Services (NGS) article IDs, and PLACES 13% diabetes as the epidemiologic floor. If that is how you already practice, the catalog will fit.
CDC PLACES (2023, crude prevalence) estimates 13% of adults — 1.0 points above the U.S. 12% figure. Obesity is 33.5%; arthritis is 21.1%. That is place-level BRFSS modeling, not a clinic census and not a Bridgeport trial.
CDC estimates 12% of the U.S. population has diabetes (40.1 million people, 2023). America's Health Rankings (BRFSS 2024) shows state adult rates from Colorado 8.4% to West Virginia 18.4%. We do not publish a made-up city diabetes count. Use national/state published rates plus your panel.
It is the Census city-proper count — useful as scale for a city under 250k. It is not a count of orthopedic groups, wound centers, or competitors. Underwrite the program against your referral sources, not against the skyline.
No. PRP (autologous) and cellular/tissue products (allograft/skin substitutes) sit on different coding and coverage paths. National Government Services (NGS) LCDs for CTPs do not automatically cover PRP injections. Build separate protocols and fee tickets.
If you operate in Connecticut and another MAC state, say it on the first call. JK will not port 1:1. We would rather split utilization than watch a sister clinic copy Bridgeport tickets into the wrong jurisdiction.
Contact us to learn how Hawk Medical supports practices in Bridgeport, CT.
Hawk Medical is a national distributor. Joe Bradley’s clinic uses the same product classes. What is local for Bridgeport is JK geography and published epidemiology — not a street address.
CDC PLACES 2023 crude rate for Bridgeport — 1.0 points above the U.S. 12% figure. Planning input, not an outcomes claim.
Connecticut Part B wound biologics follow this contractor (siblings: MA, ME, NH, NY, RI, VT). We train to the articles. We do not write coverage.
PLACES crude adult arthritis in Bridgeport. Useful for joint-program math; still needs a diagnosis and privileging.
No Bridgeport storefront. Joe Bradley is an active practice owner. 361 hctp compliant products stays in its regulatory lane — not “FDA-approved stem cell therapy.”
Experience the difference of working with a distributor who understands your practice because we operate one ourselves.